Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins

Metabolism: Clinical and Experimental
H Christian GeissKlaus G Parhofer

Abstract

Ezetimibe, a cholesterol absorption inhibitor, can be combined with statins to lower low-density lipoprotein (LDL) cholesterol. We have previously shown that ezetimibe can decrease LDL cholesterol by 16% even in patients treated by regular LDL apheresis and statins (Atherosclerosis. 2005;180:107-112). However, it is unclear whether ezetimibe decreases all LDL subfractions equally in patients with hypercholesterolemia. We therefore evaluated the effect of ezetimibe (5 weeks, 10 mg/d) on LDL subtype distribution in a placebo-controlled, double-blind randomized crossover study in 20 patients (age, 56+/-9 years; body mass index, 27.5+/-4 kg/m2) with severe hyperlipoproteinemia and coronary heart disease who are treated by statins and regular LDL apheresis. Both treatment periods (placebo and ezetimibe) were separated by a 5-week washout period. Low-density lipoprotein subtype distribution was determined at the end of each treatment period before apheresis by density gradient ultracentrifugation (LDL1, 1.020-1.024; LDL2, 1.025-1.029; LDL3, 1.030-1.034; LDL4, 1.035-1.040; LDL5, 1.041-1.047; LDL6, 1.048-1.057; LDL7, 1.058-1.066 g/mL). Overall, the LDL subtype distribution did not change significantly (large-buoyant LDL [LDL1+LDL2], 17...Continue Reading

References

Nov 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J R McNamaraE J Schaefer
Sep 27, 2001·JAMA : the Journal of the American Medical Association·H CamposF M Sacks
Jun 12, 2002·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·H C GeissK G Parhofer
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Nov 9, 2002·The American Journal of Cardiology·Carlos A DujovneUNKNOWN Ezetimibe Study Group
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Feb 15, 2003·The American Journal of Cardiology·Boris KerznerUNKNOWN Ezetimibe Study Group
Oct 15, 2003·The Journal of Clinical Endocrinology and Metabolism·Frank M Sacks, Hannia Campos
Mar 23, 2005·European Heart Journal·Michel FarnierUNKNOWN Ezetimibe Study Group

❮ Previous
Next ❯

Citations

Oct 16, 2007·International Journal of Clinical Practice·M Rizzo, K Berneis
Nov 16, 2006·Expert Opinion on Therapeutic Targets·Irene F Gazi, Dimitri P Mikhailidis
Sep 6, 2012·Expert Opinion on Pharmacotherapy·Ioanna Gouni-BertholdManfredi Rizzo
Dec 8, 2006·Expert Opinion on Biological Therapy·Irene F GaziDimitri P Mikhailidis
Feb 16, 2010·European Journal of Pharmacology·Michalis KalogirouMoses Elisaf
Nov 26, 2008·Atherosclerosis·Manfredi RizzoKaspar Berneis
May 24, 2007·Current Medical Research and Opinion·Mihalis KalogirouMoses Elisaf
Jul 22, 2008·Journal of cardiology·Shin-ichiro Miura, Keijiro Saku
Jun 20, 2012·Journal of Cardiovascular Pharmacology and Therapeutics·Yicong YeShuyang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.